Biopharmaceutical company Kite will share its latest scientific advances in cell therapy research at the 47th Virtual Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 14-17, 2021.
11 abstracts will be presented which demonstrate Kite’s commitment to innovation in cell therapy for patients with blood cancers. Alongside these, Kite will provide an updated survival analysis for axicabtagene ciloleucel (Yescarta) in relapsed/refractory diffuse large B cell lymphoma, a presentation of data for first licensed CAR T therapy in relapsed/refractory mantle cell lymphoma, autologous anti-CD19-transduced CD3+ cells (Tecartus), and two-year retrospective data on manufacturing commercial axicabtagene ciloleucel for European patients.
“We are pleased to share our advancing research and key data being presented at the virtual EBMT 2021,” said Dick Sundh, Vice President, Head of Australia, Canada and Europe (ACE), Kite. “Presentations include our pivotal ZUMA-1 survival analysis in large B cell lymphoma and a retrospective analysis of our manufacture and delivery of axicabtagene ciloleucel for European and Israeli adult patients. These data highlight the potential benefits of CAR T cell therapies, and our continued commitment to reach those patients who have limited treatment options.”
Information on attending here.
Image credit: National Cancer Institute
